Hospira, Inc. (NYSE:HSP)

CAPS Rating: 3 out of 5

A specialty pharmaceutical and medication delivery company that is focused on products that improve the productivity, safety and efficacy of patient care.

Results 1 - 19 of 19

Recs

0
Member Avatar reddingrunner (95.06) Submitted: 8/18/2015 1:38:18 PM : Outperform Start Price: $89.77 HSP Score: +8.40

estimated revenue up screen

Recs

0
Member Avatar TMTAirborne (75.34) Submitted: 8/4/2015 7:29:44 PM : Underperform Start Price: $89.60 HSP Score: -8.79

--FDA Warns Against Use of Hospira Infusion Pumps (August 1 & 3, 2015) The US Food and Drug Administration (FDA) is urging hospitals to stop using certain drug infusion pumps from Hospira. The devices could be accessed by unauthorized users through a hospital's network. The FTP and telnet ports on the devices are open and Port 8443 has a default login password. Once accessed, the pumps could be manipulated to alter drug dosages. One of the affected devices, the Hospira Simbiq Infusion Pump, has been discontinued, but is still in use at some medical facilities.
Other affected devices include the Plum A+ Infusion System v.13.4 and earlier, and the Plum A+ Infusion System v. 13.6 and earlier. Hospira plans to issue updates.
http://www.bbc.com/news/technology-33759428

Plus I find it overvalued, PE and sales.

Recs

0
Member Avatar lejaha (< 20) Submitted: 5/19/2014 5:08:02 PM : Outperform Start Price: $48.00 HSP Score: +85.21

This stock will outperform. They will continue to produce results similar the first quarter for the next few quarters.

Recs

0
Member Avatar browndovecapital (42.79) Submitted: 1/7/2012 9:43:16 PM : Outperform Start Price: $30.36 HSP Score: +145.68

dddd

Recs

0
Member Avatar bradford86 (99.76) Submitted: 1/7/2012 9:37:46 PM : Outperform Start Price: $30.36 HSP Score: +145.68

233. Hospira Inc. (NYSE: HSP) is cheap after it got murdered down from the $50's. With EPS guidance of $2.95 ballpark, this is a P/E of around 11 at present. Target: $35-$40. I think that we saw some end of year tax loss selling and that's all in the past. Clear the way for higher prices. I'm voting on this with CAPS points.

http://beta.fool.com/bradford86/2012/01/07/price-market-part-32/

Recs

0
Member Avatar monkey222 (43.72) Submitted: 12/2/2011 8:22:04 AM : Outperform Start Price: $27.99 HSP Score: +168.76

Acqusition target

Recs

0
Member Avatar latinoeconomist (26.56) Submitted: 8/1/2011 3:27:29 AM : Outperform Start Price: $51.43 HSP Score: +27.57

High growth potential.

Recs

0
Member Avatar crubenst (34.20) Submitted: 5/27/2010 11:10:01 AM : Outperform Start Price: $51.17 HSP Score: -0.21

Love their new aquisition of Javelin pharmaceuticals

Recs

0
Member Avatar dreese1 (66.68) Submitted: 2/24/2009 11:48:12 AM : Outperform Start Price: $24.98 HSP Score: +100.92

Not 100% sure of the solidity of this company. Still, it is healthcare and is likely to grow...

Recs

1
Member Avatar traderpat9 (75.88) Submitted: 12/31/2008 1:11:23 PM : Outperform Start Price: $26.79 HSP Score: +118.86

HOSPIRA-AN ABBOTT SPINOFF/GOING TO CONTINUE TO GROW DURING GOOD TIMES OR BAD

Recs

0
Member Avatar blackpower68 (38.33) Submitted: 11/15/2008 10:28:21 AM : Outperform Start Price: $29.69 HSP Score: +74.01

The economy may go up or down but clinics and hospital will need the supply room stocked.Also where is the CLOROX?

Recs

0
Member Avatar phatinvestor007 (90.93) Submitted: 10/18/2008 11:47:28 AM : Outperform Start Price: $29.77 HSP Score: +94.93

Cheaper drugs are needed

Recs

0
Member Avatar APMary (< 20) Submitted: 9/22/2008 9:19:02 AM : Underperform Start Price: $38.29 HSP Score: -76.18

1:13

Recs

0
Member Avatar zdocisin (< 20) Submitted: 4/22/2008 5:31:19 PM : Underperform Start Price: $40.90 HSP Score: -74.80

Will get caught up in its own hype, and get swallowed up by not feeding its infrastructure

Recs

1
Member Avatar qasamm (44.70) Submitted: 2/13/2008 6:21:21 PM : Outperform Start Price: $41.61 HSP Score: +69.48

With the recall of Baxter's Heprin and a scramble for hospitals to find a replacement HSP has the oportunity to fill the void and grab a big chunk of the market.

Sales should increase with this new demand.

Recs

0
Member Avatar ashishdwivedi (75.00) Submitted: 11/26/2007 11:36:41 PM : Outperform Start Price: $42.08 HSP Score: +71.27

Posted positive Earnings surprise recently. Good earning history.

Recs

0
Member Avatar DrStan (40.48) Submitted: 3/13/2007 4:10:08 PM : Underperform Start Price: $39.28 HSP Score: -81.19

I owned this stock when it split from Abbott and sold it at a profit. There are too many good competitors lined up against it.

Recs

0
Member Avatar heinfr (61.01) Submitted: 10/11/2006 12:14:57 PM : Underperform Start Price: $37.27 HSP Score: -89.39

hopsital care commodities is a tough business right now.

Recs

1
Member Avatar gailwood (96.44) Submitted: 8/24/2006 3:22:30 AM : Underperform Start Price: $35.85 HSP Score: -92.93

Overvalued.

Results 1 - 19 of 19

Featured Broker Partners


Advertisement